rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Invivyd, Inc.

IVVD · Nasdaq

Health CareBiotechnologyNot moving yet

IVVD stood above a rising 150-day average in 16 of the last 52 weekly readings, and has been out of that trend for the last 32 weeks. It is 39.9% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 32
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$125K
Insider sales, 12 months
$1.1M
Officials’ trades on record
0
Institutions holding
124 (-9)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 16 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$801K$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months1
Sale orders, 12 months20
Buyers · sellers1 · 5
WhoDidSharesTraded
Robert D. Allen IIIChief Scientific Officersold17,043at $0.842918 Aug 2026filed 18 Aug 2026
Jill AndersenChief Legal Officer, Secretarysold30,706at $0.842918 Aug 2026filed 18 Aug 2026
William E. DukeChief Financial Officersold18,425at $0.842918 Aug 2026filed 18 Aug 2026
Julie GreenChief Human Resources Officersold18,425at $0.842918 Aug 2026filed 18 Aug 2026
Timothy Edward LeeChief Commercial Officersold18,425at $0.842918 Aug 2026filed 18 Aug 2026
Robert D. Allen IIIChief Scientific Officersold20,679at $0.72217 Aug 2026filed 18 Aug 2026
Jill AndersenChief Legal Officer, Secretarysold37,256at $0.72217 Aug 2026filed 18 Aug 2026
William E. DukeChief Financial Officersold22,355at $0.72217 Aug 2026filed 18 Aug 2026
Julie GreenChief Human Resources Officersold22,355at $0.72217 Aug 2026filed 18 Aug 2026
Timothy Edward LeeChief Commercial Officersold22,355at $0.72217 Aug 2026filed 18 Aug 2026
Jill AndersenChief Legal Officer, Secretarysold34,939at $1.5818 Feb 2026filed 18 Feb 2026
Timothy Edward LeeChief Commercial Officersold20,964at $1.5818 Feb 2026filed 18 Feb 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders124-9 on the quarter
New · exited35 · 44
Reported value$202.8M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
Jupiter Topco LLCnew · filed 14 Aug 202634,173,104$30.0M+34,173,104
BVF INCadded · filed 14 Aug 202628,165,000$24.6M+8,640,000+44.3%
MAVERICK CAPITAL LTDunchanged · filed 14 Aug 202618,970,913$16.6M00.0%
PERCEPTIVE ADVISORS LLCreduced · filed 14 Aug 202618,490,636$16.1M-2,368,667−11.4%
BlackRock, Inc.added · filed 7 Aug 202616,134,885$14.1M+11,853,095+276.8%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 202610,496,507$9.2M+422,181+4.2%
M28 Capital Management LPunchanged · filed 13 Aug 20269,248,250$8.1M00.0%
Saturn V Capital Management LPreduced · filed 14 Aug 20268,392,288$7.3M-2,556,796−23.4%
Soleus Capital Management, L.P.unchanged · filed 11 Aug 20267,708,727$6.7M00.0%
Point72 Asset Management, L.P.added · filed 14 Aug 20267,542,061$6.6M+7,498,130+17068.0%
31 Mar 2023 – 30 Jun 2026
5593130Mar 23Dec 23Dec 24Sep 25Jun 26

Everyone who traded it

Ian Sheffield Company insiderDirector · last 31 Aug 20260 · 0
Marc Elia Company insiderChief Executive Officer · last 30 Aug 20263 · 0
Jill Andersen Company insiderChief Legal Officer, Secretary · last 18 Aug 20260 · 6
Julie Green Company insiderChief Human Resources Officer · last 18 Aug 20260 · 6
Robert D. Allen III Company insiderChief Scientific Officer · last 18 Aug 20260 · 6
Timothy Edward Lee Company insiderChief Commercial Officer · last 18 Aug 20260 · 6
William E. Duke Company insiderChief Financial Officer · last 18 Aug 20260 · 6
Michael Mina Company insiderCMO and Chief Epidemiologist · last 31 Jul 20260 · 0
Ajay Royan Company insiderDirector · last 19 May 20261 · 0
Kevin F. McLaughlin Company insiderDirector · last 19 May 20261 · 0
M28 Capital Management Lp Company insiderOther · last 19 May 20260 · 0
Paul Bolno Company insiderDirector · last 19 May 20260 · 0

Same industry

MRNA ModernaLeading+147%
ENTX Entera BioLeading+37%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Operating profit marginFY 2025 · to 31 Dec 2025-104%
Free cash flow marginFY 2025 · to 31 Dec 2025-109%
Return on capital employedFY 2025 · to 31 Dec 2025-22.9%
Research spendFY 2025 · to 31 Dec 202571.7%
Share count trendFY 2025 · to 26 Feb 20260.2%
Cash and equivalentsFY 2025 · to 31 Dec 2025$226.7M
Free cash flowFY 2025 · to 31 Dec 2025−$58.3M

Analyst forecasts

No analyst forecasts yet.